Europe's 'FDA' in limbo as hidden costs of Brexit continue to mount
London-based European Medicines Agency's bid to relocate sends tremors through UK's drug industry, raises public-safety concerns
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
London
WHEN it switched offices in London not long ago, the European Medicines Agency (EMA) signed a 25-year lease on a shiny new building in the east of the city.
Just two years later, the organisation is preparing to relocate again, but this time its likely move has sent tremors through Britain's pharmaceutical industry and raised fears over public safety.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
